Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region

被引：27

作者：

Tay, E. H. ^{[1
]}

Garland, S. ^{[2
]}

Tang, G. ^{[3
]}

Nolan, T. ^{[4
,5
]}

Huang, L. -M. ^{[6
]}

Orloski, L. ^{[7
]}

Lu, S. ^{[7
]}

Barr, E. ^{[7
]}

机构：

[1] KK Womens & Childrens Hosp, Singapore 229899, Singapore

[2] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic 3010, Australia

[3] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China

[4] Murdoch Childrens Res Inst, Murdoch, WA, Australia

[5] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Merck Res Labs, West Point, PA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 2008年 / 102卷 / 03期

关键词：

cervical cancer; cervical intraepithelial neoplasia; clinical trial; genital warts; human papillomavirus; prophylactic vaccine;

D O I：

10.1016/j.ijgo.2008.03.021

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective:To evaluate results of three phase 3 clinical trials of quadrivalent HPV 6/11/16/18 vaccination of young Asia-Pacific women. Methods:A total of 814 women from the Asia-Pacific region (aged 16 to 26 years) received vaccine or placebo in 1 of 3 protocols. Descriptive analyses focused on the efficacy, safety, and immunogenicity of the vaccine and the natural history of HPV disease. Results:Vaccine efficacy against disease caused by HPV types 6, 11, 16, or 18 was 100% for cervical intraepithelial neoplasia (0 vs 12 cases; 95% confidence interval [CI], 63.1%-100%) and 100% for vulvar and vaginal intraepithelial neoplasia or condylomata accuminata (0 vs 5 cases; 95% CI, -11.8% to 100%). The vaccination was highly immunogenic. Vaccine recipients experienced a significantly higher injection site adverse event rate (P=0.002). Compared with other world regions, lower rates of smoking and baseline positivity to 14 HPV types (including the vaccine types) were observed among Asia-Pacific participants. Conclusion: Prophylactic quadrivalent HPV 6/11/16/18 vaccination of young Asia-Pacific women demonstrated high efficacy, safety, and tolerability. Together with an observed low baseline HPV positivity rate, the Asia-pacific population is potentially an important cohort to benefit from vaccination. (c) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：275 / 283

页数：9

共 25 条

[11] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].

Garland, Suzanne M. ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Harper, Diane M. ;

Leodolter, Sepp ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Bryan, Janine ;

Taddeo, Frank J. ;

Railkar, Radha ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John ;

Sattler, Carlos ;

Barr, Eliav ;

Koutsky, Laura A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943

[12] Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease [J].

Lacey, Charles J. N. ;

Lowndes, Catherine M. ;

Shah, Keerti V. .

VACCINE, 2006, 24 :35-41

[13] Human papillomavirus genotype in cervical cancer: A population-based study [J].

Lai, Chyong-Huey ;

Huang, Huei-Jean ;

Hsueh, Swei ;

Chao, Angel ;

Lin, Cheng-Tao ;

Huang, Shang-Lang ;

Chao, Fang-Yu ;

Qiu, Jian-Tai ;

Hong, Ji-Hong ;

Chou, Hung-Hsueh ;

Chang, Ting-Chang ;

Chang, Chee-Jen .

INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (09) :1999-2006

[14] Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis [J].

Lai, HC ;

Peng, MY ;

Nieh, S ;

Yu, CP ;

Chang, CC ;

Lin, YW ;

Sun, CA ;

Chu, TY .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) :730-735

[15] High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan [J].

Lin, H ;

Ma, YY ;

Moh, JS ;

Ou, YC ;

Shen, SY ;

ChangChien, CC .

GYNECOLOGIC ONCOLOGY, 2006, 101 (01) :40-45

[16] Prevalence of human papillomavirus in cervical cancer: A multicenter study in China [J].

Lo, KWK ;

Wong, YF ;

Chan, MKM ;

Li, JCB ;

Poon, JS ;

Wang, VW ;

Zhu, SN ;

Zhang, TM ;

He, ZG ;

Wu, QL ;

Li, GD ;

Tam, JSL ;

Kahn, T ;

Lam, P ;

Cheung, TH ;

Chung, TKH .

INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (03) :327-331

[17] COMPARATIVE-ANALYSIS OF 2 RATES [J].

MIETTINEN, O ;

NURMINEN, M .

STATISTICS IN MEDICINE, 1985, 4 (02) :213-226

[18]

Moore Malcolm A, 2004, Asian Pac J Cancer Prev, V5, P349

[19] HPV in the etiology of human cancer [J].

Munoz, Nubia ;

Castellsague, Xavier ;

de Gonzalez, Amy Berrington ;

Gissmann, Lutz .

VACCINE, 2006, 24 :1-10

[20] Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents - A randomized controlled trial [J].

Reisinger, Keith S. ;

Block, Stan L. ;

Lazcano-Ponce, Eduardo ;

Samakoses, Rudiwilai ;

Esser, Mark T. ;

Erick, Joanne ;

Puchalski, Derek ;

Giacoletti, Katherine E. D. ;

Sings, Heather L. ;

Lukac, Suzanne ;

Alvarez, Frances B. ;

Barr, Eliav .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (03) :201-209

← 1 2 3 →